What is the current swine erysipelas vaccine market size?

The swine erysipelas vaccine market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the swine erysipelas vaccine market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driving future outlook.

What are the key drivers of the swine erysipelas vaccine market?

Increasing demand for pork and rising awareness about swine diseases are key drivers of the market.

What are the challenges facing the swine erysipelas vaccine market?

High development costs and strict regulatory frameworks are major challenges facing the market.

Which regions are leading the swine erysipelas vaccine market?

North America and Europe are leading the market due to high pork consumption and advanced animal healthcare.

Who are the top companies in the swine erysipelas vaccine market?

Top companies include Zoetis, Merck, and Boehringer Ingelheim, offering innovative vaccine solutions.

What are the future opportunities in the swine erysipelas vaccine market?

Emerging markets and technological advancements in vaccine development offer significant future opportunities.

How is technology impacting the swine erysipelas vaccine market?

Advances in biotechnology and vaccine manufacturing are improving vaccine efficacy and driving market growth.

What is the regulatory landscape for the swine erysipelas vaccine market?

Regulatory frameworks vary by region, with strict guidelines governing vaccine approval and distribution.

How is the swine erysipelas vaccine market expected to evolve in the next 5 years?

The market is expected to evolve through increased adoption of advanced vaccine technologies and rising demand.

swine erysipelas vaccine Market: Opportunity by 2034 | In-Depth Report

swine erysipelas vaccine by Application (Pharmacy, Online Sale, Others), by Types (Live, Inactivated), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

swine erysipelas vaccine Market Overview

The swine erysipelas vaccine market refers to the industry segment focused on the development, production, and distribution of vaccines for the prevention and control of erysipelas in swine. As the swine erysipelas vaccine market size is anticipated to experience significant growth, driven by increasing demand for swine erysipelas vaccine market forecast, the industry is poised for substantial expansion. The growth outlook for this market is promising, with a compound annual growth rate (CAGR) expected to be around 5-7% during the forecast period from 2026 to 2033. The current swine erysipelas vaccine market size is estimated to be approximately $340 million. Key drivers of this growth include advancements in vaccine technology, increasing awareness of animal health, and rising demand for pork and pork products globally, fueling industry expansion.

Loading chart…

Several key forces are shaping the swine erysipelas vaccine industry, including technology shifts towards more effective and safer vaccine formulations, regulations aimed at improving animal health and preventing disease outbreaks, and competitive intensity among vaccine manufacturers. The largest region for the swine erysipelas vaccine market is currently North America, while the fastest-growing region is anticipated to be Asia-Pacific, driven by rapid growth in pork production and consumption. As the market continues to evolve, understanding these dynamics will be crucial for strategic planners and business development teams to navigate the swine erysipelas vaccine market effectively.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	4.32 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zoetis; Merck; Boehringer Ingelheim; Qilu Animal Health; CAHIC; Chengdu Tianbang Biology; Jiujiang Bomeilai Biological; Jilin Zhengye Biological; Zhejiang Shihua Nuo Beiwei Biotechnology Co.,Ltd.; Hunan Zhong'an Biological Pharmaceutical Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The swine erysipelas vaccine market is poised for significant growth, driven by increasing demand for effective disease prevention measures in the swine industry. This section provides an in-depth analysis of the market dynamics, including growth drivers, restraints, opportunities, and challenges that are expected to shape the swine erysipelas vaccine market size and growth forecast.

Growth Drivers2 items

Advances in vaccine technology have improved the efficacy and safety of swine erysipelas vaccines, leading to increased adoption rates among swine farmers and contributing to the growth of the swine erysipelas vaccine market.

Government initiatives and regulations promoting animal health and disease prevention have created a favorable environment for the growth of the swine erysipelas vaccine market, with many countries implementing vaccination programs to control the spread of swine erysipelas.

Restraints2 items

The high cost of developing and manufacturing swine erysipelas vaccines can be a significant barrier to entry for new market players, limiting competition and innovation in the swine erysipelas vaccine market.

The availability of alternative disease prevention methods, such as antibiotics, can reduce the demand for swine erysipelas vaccines and hinder the growth of the swine erysipelas vaccine market.

Opportunities2 items

The increasing demand for swine erysipelas vaccines in emerging markets, particularly in Asia and Latin America, presents a significant opportunity for market players to expand their reach and increase their swine erysipelas vaccine market share.

The development of novel vaccine delivery systems and adjuvants can enhance the effectiveness and convenience of swine erysipelas vaccines, driving growth in the swine erysipelas vaccine market and improving animal health outcomes.

Challenges2 items

The swine erysipelas vaccine market is subject to fluctuations in global pork demand and supply chain disruptions, which can impact the availability and pricing of swine erysipelas vaccines.

Ensuring the safety and efficacy of swine erysipelas vaccines while minimizing the risk of adverse reactions and environmental impacts is a significant challenge for manufacturers and regulators in the swine erysipelas vaccine market.

Market Segmentation

Loading chart…

The swine erysipelas vaccine market can be segmented based on application, which includes prevention of swine erysipelas in pigs. This segment contributes to the overall market size by providing protection against the disease, thereby reducing the risk of outbreaks and promoting a healthy swine population. The application segment is crucial in the swine erysipelas vaccine segmentation as it directly impacts the demand for vaccines and drives the market growth.

The market can also be segmented based on types, which includes bacterin and live attenuated vaccines. These subtypes cater to different needs and preferences of swine farmers and veterinary professionals. The types segment is essential in understanding the market taxonomy of the swine erysipelas vaccine market, as it influences the purchasing decisions and vaccination strategies. Each subtype has its own set of advantages and disadvantages, and their unique characteristics contribute to the overall market size.

swine erysipelas vaccine Segmentation Breakdown7 items

Application

Pharmacy

Online Sale

Others

Types

Live

Inactivated

Regional Insights

Loading chart…

The swine erysipelas vaccine market growth is anticipated to be driven by various factors across different regions. In terms of regional forecast, North America is the largest region, accounting for approximately 30% of the global market, driven by factors such as high adoption rates, established infrastructure, and significant investments in the animal health industry. On the other hand, Asia Pacific is expected to be the fastest-growing region, driven by increasing demand for swine erysipelas vaccines, government initiatives, and expanding distribution networks.

Key drivers for each region include: for North America, strong ecosystem maturity, favorable policies, and high awareness among farmers; for Europe, stringent regulations, growing demand for animal protein, and increasing focus on animal health; for Asia Pacific, rapidly growing pig population, rising disease incidence, and growing investments in the animal health sector; for Latin America, growing livestock industry, increasing awareness about swine erysipelas, and expanding vaccine distribution networks; and for Middle East & Africa, growing demand for animal products, increasing focus on food security, and rising investments in the agricultural sector.

Competitive Landscape

The swine erysipelas vaccine market is moderately consolidated, with a mix of global players and local/regional companies competing on pricing, distribution, product innovation, certifications, and regulatory approvals. The swine erysipelas vaccine competitive landscape is driven by the ability of key players to navigate these competitive levers effectively. Global companies tend to have an edge in terms of distribution and regulatory approvals, while local players focus on pricing and customization to remain competitive.

Companies in this space employ various strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay ahead. However, they face challenges like margin pressure, compliance costs, and supply chain risks. Competitive differentiation is achieved through technology, service models, channel strength, customization, and cost advantages. The following companies are notable for their strategic focus:

Zoetis: regional expansion

Merck: innovation pipeline

Boehringer Ingelheim: premium pricing

Qilu Animal Health: local manufacturing

CAHIC: OEM tie-ups

Chengdu Tianbang Biology: vertical integration

Key swine erysipelas vaccine Companies10 items

Zoetis

Merck

Boehringer Ingelheim

Qilu Animal Health

CAHIC

Chengdu Tianbang Biology

Jiujiang Bomeilai Biological

Jilin Zhengye Biological

Zhejiang Shihua Nuo Beiwei Biotechnology Co.,Ltd.

Hunan Zhong'an Biological Pharmaceutical Co.,Ltd.

Market Ecosystem

The swine erysipelas vaccine ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly categorized into three segments: upstream, midstream, and downstream, with value created and captured at each stage. Understanding the swine erysipelas vaccine ecosystem is crucial for analyzing the dynamics of this market, including how value flows through the system and where control points and bottlenecks exist.

Raw material suppliers — provide vaccine components

OEMs/manufacturers — produce vaccines

Distributors/channel partners — facilitate vaccine distribution

Service providers/after-sales — offer support and maintenance

End users/buyers — purchase and administer vaccines

Regulators/standards bodies — oversee vaccine safety and efficacy

Data/analytics providers — provide market insights and trends

In this ecosystem, control points are primarily held by regulators and manufacturers, as they influence vaccine adoption through approvals and production capacities. Dependency risks arise from input constraints, such as access to raw materials, and standards approvals, which can impact vaccine availability. Switching costs and partnerships between distributors and manufacturers can also affect the ecosystem's dynamics. Furthermore, the ecosystem may differ by region due to varying regulatory requirements and market demands, highlighting the need for a nuanced understanding of the value chain analysis to navigate this complex landscape.

Recent Industry Insights

The swine erysipelas vaccine industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between vaccine manufacturers and animal health companies have led to the creation of innovative vaccination programs. Notably, the swine erysipelas vaccine market has seen a surge in mergers and acquisitions, with major players expanding their product portfolios through strategic acquisitions. Furthermore, advancements in vaccine technology have resulted in the launch of new products with improved efficacy and safety profiles.

In addition to these developments, regulatory changes have played a crucial role in shaping the swine erysipelas vaccine industry trends. Shifts in consumer and enterprise trends have also influenced the market, with a growing emphasis on animal health and wellness. Moreover, funding rounds and expansions have enabled companies to invest in research and development, driving innovation and growth in the swine erysipelas vaccine industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the swine erysipelas vaccine market. The swine erysipelas vaccine market outlook is anticipated to be attractive, driven by increasing demand for animal health products and a rising focus on preventing swine diseases. Competitive intensity is moderate, with key players investing in research and development to improve vaccine efficacy. The long-term outlook is positive, with opportunities for growth in emerging markets and innovative vaccine technologies. However, the demand-supply balance may be affected by factors such as disease outbreaks and vaccine availability. Key risk factors include regulatory changes, disease evolution, and supply chain disruptions.

12 items

1. Executive Summary

2. swine erysipelas vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global swine erysipelas vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global swine erysipelas vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global swine erysipelas vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global swine erysipelas vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global swine erysipelas vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global swine erysipelas vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global swine erysipelas vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global swine erysipelas vaccine Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global swine erysipelas vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global swine erysipelas vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global swine erysipelas vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global swine erysipelas vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global swine erysipelas vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global swine erysipelas vaccine Market Competition by Key Manufacturers

9.1. Global swine erysipelas vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global swine erysipelas vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Zoetis

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merck

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Boehringer Ingelheim

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Qilu Animal Health

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. CAHIC

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Chengdu Tianbang Biology

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Jiujiang Bomeilai Biological

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Jilin Zhengye Biological

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Zhejiang Shihua Nuo Beiwei Biotechnology Co.,Ltd.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Hunan Zhong'an Biological Pharmaceutical Co.,Ltd.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global swine erysipelas vaccine Market

Figure 4: Global swine erysipelas vaccine Market: Drivers

Figure 5: Global swine erysipelas vaccine Market: Challenges

Figure 6: Global swine erysipelas vaccine Market: Trends

Figure 7: Global swine erysipelas vaccine Market: Opportunity

Figure 8: Global swine erysipelas vaccine Market: Restraint

Figure 9: Global swine erysipelas vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global swine erysipelas vaccine Market Value (USD Million) By Region

Figure 19: Global swine erysipelas vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global swine erysipelas vaccine Market Value (USD Million) By Region

Figure 27: Global swine erysipelas vaccine Market Share (%) By: Regions (2032)

Figure 28: Global swine erysipelas vaccine Market Volume (K) By Region

Figure 29: Global swine erysipelas vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global swine erysipelas vaccine Market Value (USD Million) By Region

Figure 37: Global swine erysipelas vaccine Market Share (%) By: Regions (2032)

Figure 38: Global swine erysipelas vaccine Market Volume (K) By Region

Figure 39: Global swine erysipelas vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global swine erysipelas vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global swine erysipelas vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global swine erysipelas vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global swine erysipelas vaccine Market Value (USD Million) By Region

Table 14: Global swine erysipelas vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global swine erysipelas vaccine Market Volume (K) By Region

Table 31: Global swine erysipelas vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global swine erysipelas vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global swine erysipelas vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global swine erysipelas vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Zoetis Basic Information And Sales Area

Table 52: Zoetis. Products Portfolio

Table 53: Merck Basic Information And Sales Area

Table 54: Merck. Products Portfolio

Table 55: Boehringer Ingelheim Basic Information And Sales Area

Table 56: Boehringer Ingelheim. Products Portfolio

Table 57: Qilu Animal Health Basic Information And Sales Area

Table 58: Qilu Animal Health. Products Portfolio

Table 59: CAHIC Basic Information And Sales Area

Table 60: CAHIC. Products Portfolio

Table 61: Chengdu Tianbang Biology Basic Information And Sales Area

Table 62: Chengdu Tianbang Biology. Products Portfolio

Table 63: Jiujiang Bomeilai Biological Basic Information And Sales Area

Table 64: Jiujiang Bomeilai Biological. Products Portfolio

Table 65: Jilin Zhengye Biological Basic Information And Sales Area

Table 66: Jilin Zhengye Biological. Products Portfolio

Table 67: Zhejiang Shihua Nuo Beiwei Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 68: Zhejiang Shihua Nuo Beiwei Biotechnology Co.,Ltd.. Products Portfolio

Table 69: Hunan Zhong'an Biological Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 70: Hunan Zhong'an Biological Pharmaceutical Co.,Ltd.. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global swine erysipelas vaccine Market Value (USD Million) By Region

Table 80: Global swine erysipelas vaccine Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global swine erysipelas vaccine Market Volume (K) By Region

Table 97: Global swine erysipelas vaccine Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

swine erysipelas vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	4.32 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zoetis; Merck; Boehringer Ingelheim; Qilu Animal Health; CAHIC; Chengdu Tianbang Biology; Jiujiang Bomeilai Biological; Jilin Zhengye Biological; Zhejiang Shihua Nuo Beiwei Biotechnology Co.,Ltd.; Hunan Zhong'an Biological Pharmaceutical Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

The swine erysipelas vaccine market is subject to fluctuations in global pork demand and supply chain disruptions, which can impact the availability and pricing of swine erysipelas vaccines.

Market Segmentation

Loading chart…

swine erysipelas vaccine Segmentation Breakdown7 items

Application

Pharmacy

Online Sale

Others

Types

Live

Inactivated

Regional Insights

Loading chart…

Competitive Landscape

Zoetis: regional expansion

Merck: innovation pipeline

Boehringer Ingelheim: premium pricing

Qilu Animal Health: local manufacturing

CAHIC: OEM tie-ups

Chengdu Tianbang Biology: vertical integration

Key swine erysipelas vaccine Companies10 items

Zoetis

Merck

Boehringer Ingelheim

Qilu Animal Health

CAHIC

Chengdu Tianbang Biology

Jiujiang Bomeilai Biological

Jilin Zhengye Biological

Zhejiang Shihua Nuo Beiwei Biotechnology Co.,Ltd.

Hunan Zhong'an Biological Pharmaceutical Co.,Ltd.

Market Ecosystem

Raw material suppliers — provide vaccine components

OEMs/manufacturers — produce vaccines

Distributors/channel partners — facilitate vaccine distribution

Service providers/after-sales — offer support and maintenance

End users/buyers — purchase and administer vaccines

Regulators/standards bodies — oversee vaccine safety and efficacy

Data/analytics providers — provide market insights and trends

Recent Industry Insights

Analyst Overview

Table of Contents